top of page
28 juil. 2020
Polyphor set up a two-year, CHF 19.3 million equity-linked financing line with IRIS to ensure flexible funding for the continued development of balixafortide and its oncology/antibiotics pipeline.
Allschwil, Switzerland, July 28, 2020 - Polyphor entered a CHF 19.3 million, interest-free mandatory convertible bond program with IRIS, providing monthly financing tranches over two years that the company can suspend or terminate at will. This structure gives Polyphor financial flexibility to advance its Phase III balixafortide program and other strategic developments, with shares issued monthly upon conversion and sold on the market.
Download Polyphor press release
bottom of page